Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

The microRNA (miRNA)-34a is a key regulator of tumor suppression. It controls the
expression of a plethora of target proteins involved in cell cycle, differentiation and …

Background: MicroRNAs play essential roles in gene regulation. A substantial fraction of
microRNAs in tissues and body fluids is encapsulated in exosomes, thereby conferring …

Multiple myeloma (MM) is a tumor of transformed plasma cells. It's the second most common
hematologic cancer after non-Hodgkin lymphoma. MM is a complex disease with many …

Encapsulation of microRNAs in exosomes confers protection against degradation and a
vehicle for shuttling of microRNAs between cells and tissues, and cellular uptake by …

Inhibition of proteasome, a proteolytic complex responsible for the degradation of
ubiquitinated proteins, has emerged as a powerful strategy for treatment of multiple …

The specificity protein (Sp) transcription factors (TFs) Sp1, Sp2, Sp3 and Sp4 exhibit
structural and functional similarities in cancer cells and extensive studies of Sp1 show that it …

MicroRNAs (miRNAs) are endogenous small non-coding RNAs with the capacity to regulate
gene expression post-transcriptionally. The miRNA-29 family consists of miR-29a, miR-29b …

Multiple myeloma (MM) drug resistance (DR) is a multistep transformation process based on
a powerful interplay between bone marrow stromal cells and MM cells that allows the latter …

Purpose: Deregulated expression of miRNAs plays a role in the pathogenesis and
progression of multiple myeloma. Among upregulated miRNAs, miR-21 has oncogenic …